Indivior
INDV Nasdaq· Pharmaceuticals
Last close · Oct 26, 2026
$34.56
KIRA · Stoqly’s AI analyst, in plain words
- Indivior had $1.2B of revenue in fiscal 2025, up 4.3% on the year before.
- Its operating margin was 21.2%, up 18.0 pts: of every 100 in sales, about 21 is left after running the business.
- Indivior made $210M of net profit in fiscal 2025. From fiscal 2021 to 2025, diluted EPS grew 5.0% a year.
- Free cash flow was −$93.0M in fiscal 2025, −7.5% of revenue.
- Indivior returned $11.0M to shareholders in fiscal 2025. The diluted share count fell 3.8%.
- Indivior owes $124M more than it holds in cash, about 0.5 years of operating profit.
Market cap
$4.3B
P/E
12.4x
Revenue
$1.2B
Net income
$210M
Free cash flow
−$93.0M
Operating margin
21.2%
Indivior in 30 seconds · fiscal 2025
Are sales growing?
+4.3%
Only a little. Sales grew 4.3% last year.
Does it make a profit?
17.0%
Yes. It keeps 17.0% of every sale as profit.
Does profit turn into cash?
−7.5%
No. It spent more cash than it brought in.
Is debt under control?
0.5x
Yes. It could repay its debt with 0.5 years of operating profit.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
12.4x
One share costs 12.4 times its yearly profit per share. Typical for its sector: 28.4x.
What Indivior does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Indivior Pharmaceuticals, Inc.
- CIK
- 0001625297
Indivior · INDV
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $791M | $901M | $1.1B | $1.2B | $1.2B |
| Revenue growth | — | 13.9% | 21.3% | 8.7% | 4.3% |
| Gross margin | 83.9% | 83.1% | 84.1% | 80.6% | 80.2% |
| Operating margin | 26.9% | −9.0% | −13.9% | 3.2% | 21.2% |
| Net income | $205M | −$44.0M | −$126M | $7.0M | $210M |
| Net margin | 25.9% | −4.9% | −11.5% | 0.6% | 17.0% |
| Diluted EPS | $1.35 | −$0.32 | −$0.92 | $0.05 | $1.64 |
| Cash | |||||
| Cash from operations | $353M | −$4.0M | −$300M | $36.0M | −$27.0M |
| Capital expenditure | $4.0M | $5.0M | $8.0M | $29.0M | $66.0M |
| Free cash flow | $349M | −$9.0M | −$308M | $7.0M | −$93.0M |
| FCF margin | 44.1% | −1.0% | −28.2% | 0.6% | −7.5% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $101M | $90.0M | $33.0M | $173M | $11.0M |
| Share count change | — | −8.5% | −1.4% | −2.9% | −3.8% |
| Debt and strength | |||||
| Cash and short-term investments | $1.1B | $774M | $410M | $320M | $195M |
| Debt incl. finance leases | $242M | $240M | $243M | $333M | $319M |
| Shareholders' equity | $121M | −$15.0M | −$184M | −$337M | −$98.0M |
| Net debt / EBITDA | −3.8x | — | — | 0.2x | 0.5x |
| Current ratio | 1.8x | 1.2x | 1.0x | 0.9x | 0.7x |
| Interest coverage | 7.9x | −3.0x | −4.3x | 0.9x | 5.8x |
| Returns and quality | |||||
| Piotroski F-score | — | — | 3 | 6 | 4 |
| Altman Z'' | 5.8 | 3.0 | −1.2 | −1.6 | −0.7 |
Insiders bought, 12 months
$0.3M
7 insiders
Insiders sold, 12 months
$2.8M
2 insiders
Of sales under plans
100%
$2.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Indivior · INDV
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Indivior INDV | $4.3B | 4.3% | 21.2% | −7.5% | — | 12.4x | 4 |
| Acadia Pharmaceuticals ACAD | $3.4B | 11.9% | 9.8% | 9.8% | — | 8.9x | — |
| Alkermes ALKS | $7.7B | −5.3% | 17.2% | 32.6% | — | 116.9x | — |
| ANI Pharmaceuticals ANIP | $1.6B | 43.8% | 12.6% | 19.4% | 15.9% | 15.7x | 6 |
| Collegium Pharmaceutical COLL | $754M | 23.6% | 23.0% | 42.0% | 53.4% | 18.7x | 6 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $34.56 a share, the company is worth $4.3B: 12.4 times its earnings of the last four quarters.
Indivior grew sales faster than 1 of its 4 similar companies. Its P/E is higher than 1 of 4.
Source: SEC EDGAR XBRL filings (CIK 0001625297). Data updated October 23, 2026. For information only — not investment advice. Check the original filings before relying on any figure.